328 related articles for article (PubMed ID: 26813047)
1. Relevance of a 5-grass sublingual tablet for immunotherapy of patients with grass pollen allergy in North America.
Moingeon P; Cox L
Expert Rev Clin Immunol; 2016 Jun; 12(6):617-23. PubMed ID: 26813047
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy.
Baron-Bodo V; Horiot S; Lautrette A; Chabre H; Drucbert AS; Danzé PM; Sénéchal H; Peltre G; Galvain S; Zeldin RK; Horak F; Moingeon P
Clin Exp Allergy; 2013 Dec; 43(12):1362-73. PubMed ID: 24261946
[TBL] [Abstract][Full Text] [Related]
3. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
[TBL] [Abstract][Full Text] [Related]
4. Detection of pan-allergens in commercial pollen extracts for allergen immunotherapy.
Asero R; Mistrello G; Amato S
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):180-5. PubMed ID: 27238577
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
6. Allergen Immunotherapy for a Teenager with Seasonal Allergic Rhinitis Due to Grass Pollen: Subcutaneous or Sublingual Route?
Nelson HS; Durham SR
J Allergy Clin Immunol Pract; 2017; 5(1):52-57. PubMed ID: 28065341
[No Abstract] [Full Text] [Related]
7. Optimum treatment strategies for polyallergic patients - analysis of a large observational trial.
Shah-Hosseini K; Mioc K; Hadler M; Karagiannis E; Mösges R
Curr Med Res Opin; 2015 Dec; 31(12):2249-59. PubMed ID: 26366617
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets.
Malling HJ; Lund L; Ipsen H; Poulsen L
J Investig Allergol Clin Immunol; 2006; 16(3):162-8. PubMed ID: 16784009
[TBL] [Abstract][Full Text] [Related]
9. Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study.
Pfaar O; Richter HG; Klimek L; Sieber J; Hadler M; Karagiannis E
Biomed Res Int; 2015; 2015():584291. PubMed ID: 26351635
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Tablet Formulation on Allergen Release Kinetics and Efficiency: Comparison of Freeze-dried and Compressed Grass Pollen Sublingual Allergy Immunotherapy Tablet Formulations.
Lund K; Kito H; Skydtsgaard MB; Nakazawa H; Ohashi-Doi K; Lawton S
Clin Ther; 2019 Apr; 41(4):742-753. PubMed ID: 30885398
[TBL] [Abstract][Full Text] [Related]
11. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
12. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
[TBL] [Abstract][Full Text] [Related]
13. Five-grass-pollen sublingual immunotherapy tablet for the treatment of grass-pollen-induced allergic rhinoconjunctivitis: 5 years of experience.
Didier A; Wahn U; Horak F; Cox LS
Expert Rev Clin Immunol; 2014 Oct; 10(10):1309-24. PubMed ID: 25205329
[TBL] [Abstract][Full Text] [Related]
14. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
15. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy.
Bousquet J; Braquemond P; Feinberg J; Guerin B; Maasch H; Michel FB
Ann Allergy; 1986 Jun; 56(6):456-9. PubMed ID: 3717711
[TBL] [Abstract][Full Text] [Related]
16. Molecular sensitization patterns and influence of molecular diagnosis in immunotherapy prescription in children sensitized to both grass and olive pollen.
Martínez-Cañavate Burgos A; Torres-Borrego J; Molina Terán AB; Corzo JL; García BE; Rodríguez Pacheco R; Moreno Aguilar C; Dávila I
Pediatr Allergy Immunol; 2018 Jun; 29(4):369-374. PubMed ID: 29369414
[TBL] [Abstract][Full Text] [Related]
17. Allergens. Heterogeneity of molecular sensitization profiles in grass pollen allergy--implications for immunotherapy?
Darsow U; Brockow K; Pfab F; Jakob T; Petersson CJ; Borres MP; Ring J; Behrendt H; Huss-Marp J
Clin Exp Allergy; 2014; 44(5):778-86. PubMed ID: 24598010
[TBL] [Abstract][Full Text] [Related]
18. Sialylated Fetuin-A as a candidate predictive biomarker for successful grass pollen allergen immunotherapy.
Caillot N; Bouley J; Jain K; Mariano S; Luce S; Horiot S; Airouche S; Beuraud C; Beauvallet C; Devillier P; Chollet-Martin S; Kellenberger C; Mascarell L; Chabre H; Batard T; Nony E; Lombardi V; Baron-Bodo V; Moingeon P
J Allergy Clin Immunol; 2017 Sep; 140(3):759-770.e13. PubMed ID: 27965111
[TBL] [Abstract][Full Text] [Related]
19. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
20. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
